Ulcerative Colitis Market to Reach USD 21 Billion by 2036 at 7.6% CAGR Across the 7MM | DelveInsight

DelveInsight's "Ulcerative Colitis Market Insights, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of the ulcerative colitis, historical and forecasted epidemiology and the ulcerative colitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Ulcerative Colitis Market Report @ https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Ulcerative Colitis Market Report
• In April 2026, Abivax announced that nine scientific abstracts on obefazimod, for the treatment of moderately to severely active ulcerative colitis, would be presented at the 2026 Digestive Disease Week (DDW), held May 2-5, 2026 in Chicago, IL, highlighting Phase III ABTECT program data on efficacy, safety, and patient-reported outcomes, along with preclinical anti-fibrotic activity.
• In February 2026, presented at ECCO 2026, Phase III data for obefazimod in ulcerative colitis showed quick and early reductions in patient-reported symptoms combined with a safety profile similar to placebo.
• The Ulcerative Colitis market in the 7MM was valued at approximately USD 9,400 million in 2025 and is projected to reach USD 21,000 million in 2036, growing at a CAGR of 7.6% over the forecast period.
• According to DelveInsight estimates, in 2025, the United States accounted for approximately USD 6,600 million of the ulcerative colitis market size, although recent analyses suggest potential upside driven by increasing adoption of novel and targeted therapies.
• In 2025, there were nearly 3.3 million diagnosed prevalent cases of ulcerative colitis in the 7MM.
• The total diagnosed prevalent cases of ulcerative colitis in the United States were around 1.6 million in 2025.
• In the United States in 2025, the age group 18-44 years contributed the highest number of diagnosed prevalent cases (~962,000), followed by 45-64 years (~417,000).
• Among the EU4 countries, Germany reported the highest number of diagnosed prevalent cases of moderate to severe ulcerative colitis in 2025, with approximately 235,000 cases, whereas Italy had the lowest, totaling around 129,700 cases.
• In Japan, the number of moderate to severe diagnosed prevalent cases of ulcerative colitis was found to be 222,400 cases in 2025.
• The Ulcerative Colitis Companies include Johnson and Johnson, AbbVie, Pfizer, Eli Lilly, Abivax, Merck, Ferring Pharmaceuticals, Morphic, Roche, Roivant, Prometheus Biosciences, and others.
• Promising Ulcerative Colitis Therapies include obefazimod (ABX464), tulisokibart (MK-7240), olamkicept, and others.

Get a Free sample for the Ulcerative Colitis Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Ulcerative Colitis?
Ulcerative colitis is a chronic inflammatory bowel disease (IBD) characterized by persistent inflammation and ulceration of the inner lining of the colon. It is an idiopathic condition affecting the colonic mucosa and is clinically associated with diarrhea, abdominal discomfort, pain, and hematochezia. Disease severity and extent can vary, ranging from limited involvement of the colon to extensive inflammation affecting the entire colon. Common symptoms include diarrhea, abdominal pain, urgency to defecate, fatigue, weight loss, and bloody stools. Although the exact cause remains unknown, ulcerative colitis is believed to result from a combination of genetic susceptibility, immune system dysfunction, environmental factors, and alterations in the gut microbiota. The disease follows a relapsing-remitting course that can significantly impair quality of life, while severe cases may increase the risk of complications such as colorectal cancer, toxic megacolon, and hospitalization.

Ulcerative Colitis Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases of Ulcerative Colitis
• Age-specific Diagnosed Prevalent Cases of Ulcerative Colitis
• Severity-specific Diagnosed Prevalent Cases of Ulcerative Colitis
• Total Treated Cases of Ulcerative Colitis

Download the report to understand which factors are driving Ulcerative Colitis epidemiology trends @ https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Ulcerative Colitis Approved Therapies
• Mirikizumab (OMVOH): Eli Lilly
Mirikizumab is a monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23) to reduce intestinal inflammation in ulcerative colitis. It is approved for adult patients with moderately to severely active ulcerative colitis, particularly those with an inadequate response or intolerance to conventional therapies or biologics, and is administered as an intravenous infusion during induction followed by subcutaneous injections for maintenance. OMVOH received approval in the US, Europe, and Japan in 2023, recognized as the first selective IL-23p19 inhibitor approved for ulcerative colitis.

• Guselkumab (TREMFYA): Johnson & Johnson
Guselkumab is a monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23) to reduce intestinal inflammation associated with ulcerative colitis. It is approved for adult patients with moderately to severely active ulcerative colitis, particularly those with an inadequate response or intolerance to conventional therapies, biologics, or other advanced treatments, and is administered through intravenous induction dosing followed by subcutaneous maintenance injections. TREMFYA received US FDA approval in 2024 for ulcerative colitis.

Ulcerative Colitis Pipeline Analysis
• Obefazimod (ABX464): Abivax
ABX464 is an oral, first-in-class small molecule that selectively upregulates miR-124 in immune cells, demonstrating safety and profound anti-inflammatory activity in preclinical, Phase IIa, and Phase IIb induction trials. It is currently in Phase III (ABTECT program), with maintenance trial pivotal topline data readout expected in late Q2 2026, and anticipated US launch in 2027.

• Tulisokibart (MK-7240): Merck
Tulisokibart is an investigational humanized monoclonal antibody directed against tumor necrosis factor (TNF)-like ligand 1A (TL1A), acquired as part of Merck's acquisition of Prometheus Biosciences. It is currently in Phase III of clinical development, with a Phase II trial (NCT04996797) demonstrating greater effectiveness than placebo in inducing clinical remission in patients with moderately to severely active ulcerative colitis.

Ulcerative Colitis Companies
Johnson and Johnson, AbbVie, Pfizer, Eli Lilly, Abivax, Merck, Ferring Pharmaceuticals, Morphic, Roche, Roivant, Prometheus Biosciences, and others

Discover more about therapies set to grab major Ulcerative Colitis market share @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Ulcerative Colitis Market Outlook
The ulcerative colitis market includes therapies that induce remission, maintain disease control, and prevent relapse, as no permanent cure exists. Treatment ranges from 5-aminosalicylic acids and corticosteroids to immunomodulators, biologics, biosimilars, and oral targeted therapies based on disease severity. Growing adoption of advanced biologics and oral agents is transforming patient care. Future market growth will be supported by therapies offering improved efficacy, better safety, longer durability, convenient administration, and enhanced outcomes in refractory patients.

Scope of the Ulcerative Colitis Market Report
• Study Period: 2022-2036
• Forecast Period: 2026-2036
• Base Year: 2026
• Coverage: 7MM
• Ulcerative Colitis Companies: Johnson and Johnson, AbbVie, Pfizer, Eli Lilly, Abivax, Merck, Ferring Pharmaceuticals, and others
• Ulcerative Colitis Therapies: Guselkumab (TREMFYA), Risankizumab (SKYRIZI), Etrasimod (VELSIPITY), Mirikizumab-mrkz (OMVOH), Obefazimod (ABX464), Tulisokibart (MK-7240), Olamkicept, and others
• Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and emerging therapies
• Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis, Market entry strategies
• Ulcerative Colitis Unmet Needs, KOL's views, Analyst's views, Ulcerative Colitis Market Access and Reimbursement

To know more about Ulcerative Colitis companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Ulcerative Colitis Market Overview at a Glance
7. Disease Background and Overview of Ulcerative Colitis
8. Epidemiology and Patient Population of Ulcerative Colitis
9. Patient Journey of Ulcerative Colitis
10. Marketed Therapies
11. Emerging Drugs
12. Ulcerative Colitis: 7MM Analysis
13. Unmet Needs of Ulcerative Colitis
14. SWOT Analysis of Ulcerative Colitis
15. KOL Views of Ulcerative Colitis
16. Market Access and Reimbursement of Ulcerative Colitis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.